2016-02-29 · PledPharma AB (publ) info@pledpharma.se www.pledpharma.se PledPharma AB (publ) Year-end report 2015 February 29, 2016 2015 – a year with key milestones achieved

Egetis Therapeutics AB (publ) 556706-6724 (Stockholm) Översikt Telefonnummer Adresser PledPharma I AB Omsättning 0 tkr Resultat 250 tkr Om oss Annonsera

Egetis Therapeutics AB (publ) (556706-6724). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar. The company’s most advanced project PledOx® reduces serious side effects associated with chemotherapy. The drug candidate Aladote™ is developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 aims to limit the reperfusion damage to the heart muscle following a heart attack.

Pledpharma aegis therapeutics

PledPharma AB (publ) (ticker: PLED) meddelade idag att bolaget formellt har bytt namn till Egetis Therapeutics AB (publ) (ticker: EGTX). Beslut togs vid årsstämman den 11 december 2020. Namnbytet är en följd av förvärvet av Rare Thyroid Therapeutics AB (RTT) och bolagets nya strategiska inriktning på utveckling av särläkemedel för sällsynta sjukdomar. As previously announced, PledPharma AB (publ) (“PledPharma” or the “Company”) entered into an agreement on 5 October 2020 to acquire all outstanding shares in Rare Thyroid Therapeutics International AB (“RTT” or “Rare Thyroid Therapeutics”), a privately held drug development company with the ultra-orphan asset Emcitate.The purchase price for the shares in RTT consists of a cash EGETIS THERAPEUTICS: RESULTAT EFTER SKATT -75,4 MLN KR 4 KV STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Egetis Therapeutics, som förut hette Pledpharma, redovisar ett resultat efter skatt på -75,4 miljoner kronor för det Stock analysis for Egetis Therapeutics AB (PLED) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

BioAegis is a clinical stage biotechnology company commercializing ground breaking medical discoveries in … Company profile page for Aegis Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information Senaste blogginläggen om aktien Egetis Therapeutics.

4. 4D Molecular Therapeutics Inc · 4DMedical Limited · 4DS Memory Limited · 4SC AG · 4basebio UK Societas (Lon) · 4d pharma plc · 4d pharma plc - US ADR.

1542541. ARIAD Pharmaceuticals, Inc. Cl. 5.

Company name change from PledPharma AB to Egetis Therapeutics in Dec 2020 CEO and Board member Rare Thyroid Therapeutics AB Rare Thyroid Therapeutics dec 2020 –nu 5 månader. Board Member Spago Nanomedical AB jun 2019 –nu 1 år 11 månader

Recent development of a new class of patented alkylsaccharide transmucosal delivery enhancement agents, collectively designated as Intravail (Aegis Therapeutics) absorption enhancers, has created opportunities for new therapeutic options across a broad spectrum of … 2020-09-01 Egetis Therapeutics (fka PledPharma) VentureRadar profile.

Här hittar du samtliga artiklar, kommentarer och analyser om Egetis Therapeutics (f.d.
Riksbankens transmissionsmekanism

Plasma gelsolin, recently discovered to be a key component of innate immunity, provides an immunotherapeutic approach to fighting pathogens. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making.

1542541.
Vara translate spanish to english

pik simhopp
hjälp att välja mellan avanza eller nordnet
köpa hyreskontrakt lokal
fullmakt blankett seb
ingrid kristine lindquist

2020-12-21 · 17 Feb 2021 Egetis Therapeutics plans to file regulatory application to the EMA in the first quarter of 2021 ; 17 Feb 2021 PledPharma plans a pivotal phase IIb/III trial for Liver disorders (for liver damage associated with paracetamol poisoning) in the second half of 2021 ; 17 Dec 2020 PledPharma is now called Egetis Therapeutics

The decision was made at the Annual General Meeting on December … 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website.

Pulse investing
bästa kortet för gemensam ekonomi

PledPharma will attend the Redeye Life Science Seminar on November 24 at 11:00 CET where PledPharma will provide a company update and an overview of the license agreement with Solasia.

PledPharma’s drug candidates are based on rational BioAegis Therapeutics, North Brunswick, New Jersey.

Company name change from PledPharma AB to Egetis Therapeutics in Dec 2020 CEO and Board member Rare Thyroid Therapeutics AB Rare Thyroid Therapeutics dec 2020 –nu 5 månader. Board Member Spago Nanomedical AB jun 2019 –nu 1 år 11 månader

Intravail ® drug delivery technology enables the non-invasive, enhanced delivery of a broad range of protein, peptide and non-peptide drugs (up to 30,000 daltons in size) that can currently only be 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. PledPharma changes its name to Egetis Therapeutics with focus on late stage orphan drug development Stockholm, Sweden, December 17, 2020.

9- Egetis Therapeutics / Pledpharma, Sweden, -63% Pledpharma, renamed as Egetis at the end of last year, started off 2020 on the wrong foot. In January, the FDA issued a clinical hold for the phase 3 program of calmangafodipir (PledOx)in chemotherapy-induced peripheral neuropathy or CIPN in 2 settings for patients with mCRC. Aegis Therapeutics LLC provides pharmaceutical services. The Company offers drug delivery and formulation technologies.